Compare Hut 8 Corp (HUT) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hut 8 Corp vs State Street SPDR S&P Biotech ETF — how do they compare? Hut 8 Corp trades at $81.25 (market cap $9.82B), while State Street SPDR S&P Biotech ETF trades at $153.88 (market cap $10.11B). The key difference: Hut 8 Corp and State Street SPDR S&P Biotech ETF are close in size by market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Hut 8 Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Hut 8 Corp for 11 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| HUT | XBI | |
|---|---|---|
Market Cap | $9.82B | $10.11B |
Volume | 10,272,678 | 12,903,266 |
Sector | Financials | Broad Market / Factor |
52-Week High | $133.02 | $169.55 |
52-Week Low | $33.76 | $104.99 |
Typical Hold Time | 11 Days | 38 Days |
Enterprise Value | $17.25B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HUT's stock trades at $80.25, down 10.13% over 24 hours, reflecting bearish technical signals amid weak financials. The company reported a net loss of $226.15 million for 2025, with negative cash flow from operations, though it secured a $1.07 billion credit facility to bolster liquidity. Analyst consensus remains strongly bullish with a $162.69 price target, driven by optimism around its AI infrastructure contracts.
The outlook hinges on HUT's ability to monetize its AI data center pipeline and achieve profitability. Key risks include persistent losses, high debt levels, and execution challenges in a competitive market. The stock offers high-reward potential if the company delivers on its growth strategy, but investors face significant downside if operational improvements falter.
XBI trades at $153.84, up 2.4% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure offers broad biotech exposure, benefiting from M&A activity and positive clinical catalysts, though key financial ratios are unavailable. Recent news highlights sector optimism driven by cancer vaccine breakthroughs and improved capital access.
Outlook is mixed: bullish sentiment from innovation and M&A supports growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst consensus is neutral (100% Hold), suggesting cautious optimism amid technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hut 8 Corp
Hut 8 is one of North America's largest digital asset miners and infrastructure providers. It operates diversified data centers supporting Bitcoin mining and high-performance computing (HPC) for AI.
Read more on HUT →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
